BSD Medical’s MicroThermX® Featured in a Presentation at Clinical Interventional Oncology Conference

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, today announced that the Company’s MicroThermX Microwave Ablation System (MicroThermX) technology was presented in a session at the 6th Annual Symposium on Clinical Interventional Oncology (CIO) held in Miami.

The 2014 CIO conference was attended by more than 500 physicians, scientists, researchers and health professionals from the U.S. and 30 international countries. The MicroThermX technology was featured in an educational session discussing the use of ablation technologies in the treatment of soft-tissue tumors that occur in liver, lung, and kidneys.

“Our MicroThermX technology was highlighted at this leading industry conference that focuses on some of the most viable and sought-after treatments in interventional oncology,” said Brian Ferrand, V.P., Domestic Sales. “Interventional radiologists looking to expand their practices often consider interventional oncology as the next logical step forward. We are delighted that the benefits of microwave ablation and the MicroThermX technology were presented to this targeted audience. BSD held a well-attended workshop and had good traffic at the MicroThermX booth,” added Mr. Ferrand. “We are making strong progress on increasing our brand awareness in the interventional oncology marketplace.”

Microwave ablation has multiple advantages over radiofrequency ablation (RFA). These advantages include the ability to accommodate multiple applicators, thereby increasing the flexibility of its use, and the ability to ablate large volumes of tissue in shorter periods of time. The MicroThermX System features ease of mobility and compact size, which is smaller than competing systems.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused microwave energy and radiofrequency (RF). BSD’s product lines include ablation and hyperthermia treatment systems. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and well established distribution in the United States, Europe and Asia. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

Forward-Looking Statements

Statements contained in this press release that are not historical facts, including statements relating to our 2014 plans, are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission, including the market demand for our MicroThermX® products and the regulatory requirements we face. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.